ResearcherWenzhou Medical UniversityActive in the last 2 years

Xin Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5395-9130; OpenAlex author ID A5100352152. Sources: OpenAlex.

Their work

Papers: 6 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 11

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: 2 papers · 2023: 2 papers · 2024: 1 paper

Papers 6

Retraction Note: Palmitoyl transferases act as novel drug targets for pancreatic cancer. Co-author DOI 10.1186/s12967-024-05202-x ↗
Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor microenvironment. Co-author DOI 10.1016/j.biopha.2023.114567 ↗
Palmitoyl transferases act as novel drug targets for pancreatic cancer. Co-author DOI 10.1186/s12967-023-04098-3 ↗
Cuprotosis-Related Genes: Predicting Prognosis and Immunotherapy Sensitivity in Pancreatic Cancer Patients. Co-author DOI 10.1155/2022/2363043 ↗
Neoadjuvant chemoradiation plus surgery for resectable and borderline resectable pancreatic cancer compared to upfront surgery: a meta-analysis of randomized c… Last author DOI 10.21203/rs.3.rs-1493513/v1 ↗
Identifying Drug Targets in Pancreatic Ductal Adenocarcinoma Through Machine Learning, Analyzing Biomolecular Networks, and Structural Modeling. Co-author DOI 10.3389/fphar.2020.00534 ↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Keke Huang · 3 shared papers, 2023–2024 · strength 0.73
Zhiqing Lin · 3 shared papers, 2023–2024 · strength 0.73
Zhi-Yong Xiang · 1 shared paper, 2022 · strength 0.20
- Paper Neoadjuvant chemoradiation plus surgery for resectable and borderline resectable pancreatic cancer compared to upfront … DOI 10.21203/rs.3.rs-1493513/v1 ↗
Hui Guo · 1 shared paper, 2023 · strength 0.15
- Paper Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor m… DOI 10.1016/j.biopha.2023.114567 ↗
Peng Zhang · 1 shared paper, 2023 · strength 0.15
- Paper Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor m… DOI 10.1016/j.biopha.2023.114567 ↗
Jianmin Wu · 1 shared paper, 2023 · strength 0.15
- Paper Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor m… DOI 10.1016/j.biopha.2023.114567 ↗
Wei Mei Guo · 1 shared paper, 2023 · strength 0.15
- Paper Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor m… DOI 10.1016/j.biopha.2023.114567 ↗
Yingkun Xu · 1 shared paper, 2022 · strength 0.15
- Paper Cuprotosis-Related Genes: Predicting Prognosis and Immunotherapy Sensitivity in Pancreatic Cancer Patients. DOI 10.1155/2022/2363043 ↗
Shengchun Liu · 1 shared paper, 2022 · strength 0.15
- Paper Cuprotosis-Related Genes: Predicting Prognosis and Immunotherapy Sensitivity in Pancreatic Cancer Patients. DOI 10.1155/2022/2363043 ↗
Wenying Yan · 1 shared paper, 2020 · strength 0.12
- Paper Identifying Drug Targets in Pancreatic Ductal Adenocarcinoma Through Machine Learning, Analyzing Biomolecular Networks,… DOI 10.3389/fphar.2020.00534 ↗
Guang Hu · 1 shared paper, 2020 · strength 0.12
- Paper Identifying Drug Targets in Pancreatic Ductal Adenocarcinoma Through Machine Learning, Analyzing Biomolecular Networks,… DOI 10.3389/fphar.2020.00534 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.